US equities
|
NVDA
$240.18
▲+0.53%
SPCX
$172.30
▲+0.71%
MU
$1,061.11
▼-0.27%
MRVL
$289.76
▲+6.82%
AMD
$654.73
▲+3.64%
INTC
$114.76
▼-1.23%
AVGO
$378.22
▲+4.33%
TSLA
$380.34
▲+0.42%
NVDA
$240.18
▲+0.53%
SPCX
$172.30
▲+0.71%
MU
$1,061.11
▼-0.27%
MRVL
$289.76
▲+6.82%
AMD
$654.73
▲+3.64%
INTC
$114.76
▼-1.23%
AVGO
$378.22
▲+4.33%
TSLA
$380.34
▲+0.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Adaptive Biotechnologies Corporation - Common Stock
(NQ:
ADPT
)
27.40
-2.44 (-8.18%)
Delayed Quote
Updated: 2:27 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptive Biotechnologies Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
September 25, 2026
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
September 17, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 01, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Q2 Earnings Call Highlights
↗
July 29, 2026
Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year...
Via
MarketBeat
Topics
Earnings
Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance
↗
July 29, 2026
Via
Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance
↗
May 05, 2026
Via
Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability
↗
February 05, 2026
Via
Chartmill
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
July 29, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
↗
July 12, 2026
Harlan Robins liquidated 386,240 shares under a pre-scheduled Rule 10b5-1 trading plan, retaining over 1 million shares worth $21.6 million.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
July 09, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
June 17, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
June 15, 2026
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
June 15, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
↗
June 14, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong year-over-year share gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
↗
June 03, 2026
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted...
Via
MarketBeat
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
May 29, 2026
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
From
Adaptive Biotechnologies
Via
GlobeNewswire
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
↗
May 26, 2026
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
May 21, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive (ADPT) Q1 2026 Earnings Transcript
↗
May 06, 2026
Adaptive (ADPT) Q1 2026 Earnings Transcript
Via
The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
May 05, 2026
Via
Chartmill
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
May 05, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
↗
May 04, 2026
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
↗
April 20, 2026
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
↗
April 18, 2026
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
April 15, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
↗
April 08, 2026
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look
↗
March 30, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year
↗
March 26, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price
↗
March 26, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech (ADPT) Earnings Call Transcript
↗
February 05, 2026
Adaptive Biotech (ADPT) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
Next >
